Pharmacokinetic analysis of dodecanedioic acid in humans from bolus data

ABSTRACT. Background: Excretion and tissue uptake of dodecanedioic acid (C12), a proposed alternative fuel substrate, was investigated in humans by bolus experiments. Methods: Seven overnight-fasting healthy male volunteers received IV a bolus (1 g) of C12. Blood samples were collected after C12 administra-tion at intervals of 15 minutes, and C12 serum concentration was measured by high-performance liquid chromatography. C12 ex-cretion in 24-hour urine was measured. Binding of C12 in human serum was determined in separate equilibrium dialysis experi-ments by means of an isotopic compound (disodic salt of (1,12)4C-dodecanedioic acid). A two-compartment model was used for describing C12 kinetics. Results: The excreted amount of C12 in 24-hour urine was found to be, on the average, 1.62 % of administered dose. The apparent number of binding sites per al-bumin molecule was 3.1 ± 0.2 (estimate ± SE) with an affinit